Prof. Dr. Jens Huober
Chefarzt/Chefärztin
Brustzentrum St.Gallen, Medizinische Onkologie und Hämatologie · Dept. IV, Dept. I
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2022.
Thill M, Luftner D, Kolberg-Liedtke C, Albert U, Banys-Paluchowski M, Bauerfeind I, Blohmer J, Budach W, Dall P, Fallenberg E, Fasching P, Fehm T, Friedrich M, Gerber B, Gluz O, Harbeck N, Heil J, Huober J, Jackisch C, Kreipe H, Krug D, Kühn T, Kümmel S, Loibl S, Lux M, Maass N, Mundhenke C, Nitz U, Park-Simon T, Reimer T, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, Sinn H, Solbach C, Solomayer E, Stickeler E, Thomssen C, Untch M, Witzel I, Wöckel A, Müller V, Janni W, Ditsch N. AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2022. Breast Care (Basel) 2022; 17:421-429.
02.05.2022AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2022.
02.05.2022Breast Care (Basel) 2022; 17:421-429
Thill Marc, Luftner Diana, Kolberg-Liedtke Cornelia, Albert Ute-Susann, Banys-Paluchowski Maggie, Bauerfeind Ingo, Blohmer Jens-Uwe, Budach Wilfried, Dall Peter, Fallenberg Eva Maria, Fasching Peter A, Fehm Tanja, Friedrich Michael, Gerber Bernd, Gluz Oleg, Harbeck Nadia, Heil Jörg, Huober Jens, Jackisch Christian, Kreipe Hans-Heinrich, Krug David, Kühn Thorsten, Kümmel Sherko, Loibl Sibylle, Lux Michael, Maass Nicolai, Mundhenke Christoph, Nitz Ulrike, Park-Simon Tjoung-Won, Reimer Toralf, Rhiem Kerstin, Rody Achim, Schmidt Marcus, Schneeweiss Andreas, Schütz Florian, Sinn Hans-Peter, Solbach Christine, Solomayer Erich-Franz, Stickeler Elmar, Thomssen Christoph, Untch Michael, Witzel Isabell, Wöckel Achim, Müller Volkmar, Janni Wolfgang, Ditsch Nina
Practice-Changing Perspectives regarding Systemic Therapy in Early Breast Cancer: Opinions of German Experts regarding the 17th St. Gallen International Consensus Conference
Kolberg-Liedtke C, Untch M, Thomssen C, Schneeweiss A, Müller V, Loibl S, Kühn T, Krug D, Janni W, Jackisch C, Huober J, Harbeck N, Haidinger R, Fasching P, Denkert C, Budach W, Brucker S, Luftner D, Thill M. Practice-Changing Perspectives regarding Systemic Therapy in Early Breast Cancer: Opinions of German Experts regarding the 17th St. Gallen International Consensus Conference. Breast Care (Basel) 2022; 17:336-345.
08.04.2022Practice-Changing Perspectives regarding Systemic Therapy in Early Breast Cancer: Opinions of German Experts regarding the 17th St. Gallen International Consensus Conference
08.04.2022Breast Care (Basel) 2022; 17:336-345
Kolberg-Liedtke Cornelia, Untch Michael, Thomssen Christoph, Schneeweiss Andreas, Müller Volkmar, Loibl Sibylle, Kühn Thorsten, Krug David, Janni Wolfgang, Jackisch Christian, Huober Jens, Harbeck Nadia, Haidinger Renate, Fasching Peter A, Denkert Carsten, Budach Wilfried, Brucker Sara Y, Luftner Diana, Thill Marc
New antibody-drug conjugates (ADCs) in breast cancer-an overview of ADCs recently approved and in later stages of development.
Koster K, Huober J, Jörger M. New antibody-drug conjugates (ADCs) in breast cancer-an overview of ADCs recently approved and in later stages of development. Explor Target Antitumor Ther 2022; 3:27-36.
24.02.2022New antibody-drug conjugates (ADCs) in breast cancer-an overview of ADCs recently approved and in later stages of development.
24.02.2022Explor Target Antitumor Ther 2022; 3:27-36
Koster Kira-Lee, Huober Jens, Jörger Markus
Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase 3 trial
Geyer C, Symmans W, Rastogi P, Sohn J, Young R, Wright G, Harkness C, McIntyre K, Yardley D, Dunbar M, Metzger O, Ponce Lorenzo J, Sikov W, Huober J, Rugo H, Wolmark N, O'Shaughnessy J, Maag D, Untch M, Golshan M, Loibl S. Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase 3 trial. Ann Oncol 2022
27.01.2022Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase 3 trial
27.01.2022Ann Oncol 2022
Geyer C E, Symmans W F, Rastogi P, Sohn J, Young R, Wright G S, Harkness C, McIntyre K, Yardley D, Dunbar M, Metzger O, Ponce Lorenzo J, Sikov W M, Huober Jens, Rugo H S, Wolmark N, O'Shaughnessy J, Maag D, Untch M, Golshan M, Loibl S
Pathological Response in the Breast and Axillary Lymph Nodes after Neoadjuvant Systemic Treatment in Patients with Initially Node-Positive Breast Cancer Correlates with Disease Free Survival: An Exploratory Analysis of the GeparOcto Trial
Gerber B, Untch M, Kast K, Jackisch C, Thomalla J, Seither F, Blohmer J, Rhiem K, Fasching P, Nekljudova V, Loibl S, Hahn M, Klare P, Ataseven B, Schneeweiss A, Möbus V, Golatta M, Tesch H, Krug D, Hanusch C, Denkert C, Lübbe K, Heil J, Huober J, Kühn T. Pathological Response in the Breast and Axillary Lymph Nodes after Neoadjuvant Systemic Treatment in Patients with Initially Node-Positive Breast Cancer Correlates with Disease Free Survival: An Exploratory Analysis of the GeparOcto Trial. Cancers (Basel) 2022; 14
20.01.2022Pathological Response in the Breast and Axillary Lymph Nodes after Neoadjuvant Systemic Treatment in Patients with Initially Node-Positive Breast Cancer Correlates with Disease Free Survival: An Exploratory Analysis of the GeparOcto Trial
20.01.2022Cancers (Basel) 2022; 14
Gerber Bernd, Untch Michael, Kast Karin, Jackisch Christian, Thomalla Jörg, Seither Fenja, Blohmer Jens-Uwe, Rhiem Kerstin, Fasching Peter A, Nekljudova Valentina, Loibl Sibylle, Hahn Markus, Klare Peter, Ataseven Beyhan, Schneeweiss Andreas, Möbus Volker, Golatta Michael, Tesch Hans, Krug David, Hanusch Claus, Denkert Carsten, Lübbe Kristina, Heil Jörg, Huober Jens, Kühn Thorsten
Cancer cells resist antibody-mediated destruction by neutrophils through activation of the exocyst complex
van Rees D, Saura C, Di Cosimo S, Huober J, Roylance R, Kim S, Kuijpers T, van Bruggen R, K van den Berg T, Guillaume S, Izquierdo M, El-Abed S, Bouti P, Klein B, Verkuijlen P, van Houdt M, Schornagel K, Tool A, Venet D, Sotiriou C, Matlung H. Cancer cells resist antibody-mediated destruction by neutrophils through activation of the exocyst complex. J Immunother Cancer 2022; 10
01.01.2022Cancer cells resist antibody-mediated destruction by neutrophils through activation of the exocyst complex
01.01.2022J Immunother Cancer 2022; 10
van Rees Dieke J, Saura Cristina, Di Cosimo Serena, Huober Jens, Roylance Rebecca, Kim Sung-Bae, Kuijpers Taco W, van Bruggen Robin, K van den Berg Timo, Guillaume Sébastien, Izquierdo Miguel, El-Abed Sarra, Bouti Panagiota, Klein Bart, Verkuijlen Paul J H, van Houdt Michel, Schornagel Karin, Tool Anton T J, Venet David, Sotiriou Christos, Matlung Hanke L
Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial
Blohmer J, Jackisch C, Rhiem K, Solbach C, Hanusch C, Seither F, Denkert C, Engels K, Nekljudova V, Loibl S, Thill M, Huober J, Link T, Reinisch M, Just M, Untch M, Stötzer O, Fasching P, Schneeweiss A, Wimberger P, Seiler S, GBG and AGO-B. Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial. JAMA Oncol 2022; 8:1010-1018.
01.01.2022Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial
01.01.2022JAMA Oncol 2022; 8:1010-1018
Blohmer Jens-Uwe, Jackisch Christian, Rhiem Kerstin, Solbach Christine, Hanusch Claus, Seither Fenja, Denkert Carsten, Engels Knut, Nekljudova Valentina, Loibl Sibylle, Thill Marc, Huober Jens, Link Theresa, Reinisch Mattea, Just Marianne, Untch Michael, Stötzer Oliver, Fasching Peter A, Schneeweiss Andreas, Wimberger Pauline, Seiler Sabine, GBG and AGO-B
What if the future of HER2-positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study
Pizzamiglio S, Huober J, Ellard S, Rimm D, Gombos A, Daidone M, Verderio P, Tagliabue E, Di Cosimo S, Nuciforo P, Bajji M, Cosentino G, Ciniselli C, De Cecco L, Cataldo A, Plantamura I, Triulzi T, El-Abed S, Wang Y, Iorio M. What if the future of HER2-positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study. Cancer Med 2021; 11:332-339.
17.12.2021What if the future of HER2-positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study
17.12.2021Cancer Med 2021; 11:332-339
Pizzamiglio Sara, Huober Jens, Ellard Susan L, Rimm David L, Gombos Andrea, Daidone Maria Grazia, Verderio Paolo, Tagliabue Elda, Di Cosimo Serena, Nuciforo Paolo, Bajji Mohammed, Cosentino Giulia, Ciniselli Chiara M, De Cecco Loris, Cataldo Alessandra, Plantamura Ilaria, Triulzi Tiziana, El-Abed Sarra, Wang Yingbo, Iorio Marilena V
Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program
Müller V, Müller L, Janni W, Wimberger P, Jäger B, Pantel K, Riethdorf S, Harbeck N, Fehm T, Hoffmann O, Rübner M, Huober J, Banys-Paluchowski M, Friedl T, Fasching P, Schneeweiss A, Hartkopf A, Wallwiener D, Rack B, Meier-Stiegen F, DETECT study group. Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program. ESMO Open 2021; 6:100299.
25.11.2021Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program
25.11.2021ESMO Open 2021; 6:100299
Müller V, Müller L, Janni W, Wimberger P, Jäger B, Pantel K, Riethdorf S, Harbeck N, Fehm T, Hoffmann O, Rübner M, Huober Jens, Banys-Paluchowski M, Friedl T W P, Fasching P A, Schneeweiss A, Hartkopf A, Wallwiener D, Rack B, Meier-Stiegen F, DETECT study group
Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer
Schneeweiss A, Blohmer J, Fasching P, Solbach C, Schmutzler R, Huober J, Rhiem K, Nekljudova V, Lübbe K, Loibl S, Jackisch C, Untch M, Link T, Michel L, Möbus V, Tesch H, Klare P, Hahnen E, Denkert C, Kast K, Pohl-Rescigno E, Hanusch C, GBG and AGO-B. Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer. Eur J Cancer 2021
17.11.2021Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer
17.11.2021Eur J Cancer 2021
Schneeweiss Andreas, Blohmer Jens-Uwe, Fasching Peter A, Solbach Christine, Schmutzler Rita K, Huober Jens, Rhiem Kerstin, Nekljudova Valentina, Lübbe Kristina, Loibl Sibylle, Jackisch Christian, Untch Michael, Link Theresa, Michel Laura L, Möbus Volker, Tesch Hans, Klare Peter, Hahnen Eric, Denkert Carsten, Kast Karin, Pohl-Rescigno Esther, Hanusch Claus, GBG and AGO-B
Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness
Metzger-Filho O, von Minckwitz G, Rastogi P, Li L, Cheng L, Maag D, Wolmark N, Denkert C, Symmans W, Geyer C, Loibl S, Sikov W, Golshan M, Collier K, Asad S, Ansell P, Watson M, Bae J, Cherian M, O'Shaughnessy J, Untch M, Rugo H, Huober J, Stover D. Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness. NPJ Breast Cancer 2021; 7:142.
11.11.2021Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness
11.11.2021NPJ Breast Cancer 2021; 7:142
Metzger-Filho Otto, von Minckwitz Gunter, Rastogi Priya, Li Lang, Cheng Lijun, Maag David, Wolmark Norman, Denkert Carsten, Symmans W Fraser, Geyer Charles E, Loibl Sibylle, Sikov William M, Golshan Mehra, Collier Katharine, Asad Sarah, Ansell Peter J, Watson Mark, Bae Junu, Cherian Mathew, O'Shaughnessy Joyce, Untch Michael, Rugo Hope S, Huober Jens, Stover Daniel G
Correction: AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update
Ditsch N, Rody A, Rhiem K, Reimer T, Park-Simon T, Nitz U, Mundhenke C, Möbus V, Maass N, Lux M, Luftner D, Schmidt M, Schneeweiss A, Thill M, Wöckel A, Witzel I, Untch M, Thomssen C, Stickeler E, Solomayer E, Solbach C, Sinn H, Schütz F, Loibl S, Kümmel S, Blohmer J, Bauerfeind I, Albert U, Krug D, Jackisch C, Kolberg-Liedtke C, Banys-Paluchowski M, Müller V, Janni W, Kühn T, Budach W, Dall P, Kreipe H, Huober J, Heil J, Harbeck N, Hanf V, Gluz O, Gerber B, Fehm T, Fasching P, Fallenberg E, Friedrich M. Correction: AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update. Geburtshilfe Frauenheilkd 2021; 81:e31.
22.10.2021Correction: AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update
22.10.2021Geburtshilfe Frauenheilkd 2021; 81:e31
Ditsch Nina, Rody Achim, Rhiem Kerstin, Reimer Toralf, Park-Simon Tjoung-Won, Nitz Ulrike, Mundhenke Christoph, Möbus Volker, Maass Nicolai, Lux Michael Patrick, Luftner Diana, Schmidt Marcus, Schneeweiss Andreas, Thill Marc, Wöckel Achim, Witzel Isabell, Untch Michael, Thomssen Christoph, Stickeler Elmar, Solomayer Erich-Franz, Solbach Christine, Sinn Hans-Peter, Schütz Florian, Loibl Sibylle, Kümmel Sherko, Blohmer Jens, Bauerfeind Ingo, Albert Ute-Susann, Krug David, Jackisch Christian, Kolberg-Liedtke Cornelia, Banys-Paluchowski Maggie, Müller Volkmar, Janni Wolfgang, Kühn Thorsten, Budach Wilfried, Dall Peter, Kreipe Hans-Heinrich, Huober Jens, Heil Jörg, Harbeck Nadia, Hanf Volker, Gluz Oleg, Gerber Bernd, Fehm Tanja, Fasching Peter A, Fallenberg Eva M, Friedrich Michael
AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update
Ditsch N, Rody A, Rhiem K, Reimer T, Park-Simon T, Nitz U, Mundhenke C, Möbus V, Maass N, Lux M, Luftner D, Schmidt M, Schneeweiss A, Thill M, Wöckel A, Witzel I, Untch M, Thomssen C, Stickeler E, Solomayer E, Solbach C, Sinn H, Schütz F, Loibl S, Kümmel S, Blohmer J, Bauerfeind I, Albert U, Krug D, Jackisch C, Kolberg-Liedtke C, Banys-Pachulowski M, Müller V, Janni W, Kühn T, Budach W, Dall P, Kreipe H, Huober J, Heil J, Harbeck N, Hanf V, Gluz O, Gerber B, Fehm T, Fasching P, Fallenberg E, Friedrich M. AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update. Geburtshilfe Frauenheilkd 2021; 81:1112-1120.
06.10.2021AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update
06.10.2021Geburtshilfe Frauenheilkd 2021; 81:1112-1120
Ditsch Nina, Rody Achim, Rhiem Kerstin, Reimer Toralf, Park-Simon Tjoung-Won, Nitz Ulrike, Mundhenke Christoph, Möbus Volker, Maass Nicolai, Lux Michael Patrick, Luftner Diana, Schmidt Marcus, Schneeweiss Andreas, Thill Marc, Wöckel Achim, Witzel Isabell, Untch Michael, Thomssen Christoph, Stickeler Elmar, Solomayer Erich-Franz, Solbach Christine, Sinn Hans-Peter, Schütz Florian, Loibl Sibylle, Kümmel Sherko, Blohmer Jens, Bauerfeind Ingo, Albert Ute-Susann, Krug David, Jackisch Christian, Kolberg-Liedtke Cornelia, Banys-Pachulowski Maggie, Müller Volkmar, Janni Wolfgang, Kühn Thorsten, Budach Wilfried, Dall Peter, Kreipe Hans-Heinrich, Huober Jens, Heil Jörg, Harbeck Nadia, Hanf Volker, Gluz Oleg, Gerber Bernd, Fehm Tanja, Fasching Peter A, Fallenberg Eva M, Friedrich Michael
Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis
Pizzamiglio S, Cappelletti V, Cinieri S, Piccart M, Daidone M, Pruneri G, Colombo M, Tagliabue E, Verderio P, Huober J, Nuciforo P, Izquierdo M, Ciniselli C, Triulzi T, Gargiuli C, De Cecco L, de Azambuja E, Fumagalli D, Sotiriou C, Harbeck N, Di Cosimo S. Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis. Clin Cancer Res 2021; 27:6307-6313.
21.09.2021Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis
21.09.2021Clin Cancer Res 2021; 27:6307-6313
Pizzamiglio Sara, Cappelletti Vera, Cinieri Saverio, Piccart Martine, Daidone Maria Grazia, Pruneri Giancarlo, Colombo Mario Paolo, Tagliabue Elda, Verderio Paolo, Huober Jens, Nuciforo Paolo, Izquierdo Miguel, Ciniselli Chiara Maura, Triulzi Tiziana, Gargiuli Chiara, De Cecco Loris, de Azambuja Evandro, Fumagalli Debora, Sotiriou Christos, Harbeck Nadia, Di Cosimo Serena
Ki67 as Proliferative Marker in Patients with Early Breast Cancer and Its Association with Clinicopathological Factors
De Gregorio A, Friedl T, Hering E, Widschwendter P, De Gregorio N, Bekes I, Janni W, Davut D, Huober J. Ki67 as Proliferative Marker in Patients with Early Breast Cancer and Its Association with Clinicopathological Factors. Oncology 2021; 99:780-789.
14.09.2021Ki67 as Proliferative Marker in Patients with Early Breast Cancer and Its Association with Clinicopathological Factors
14.09.2021Oncology 2021; 99:780-789
De Gregorio Amelie, Friedl Thomas Wolfram Paul, Hering Eva, Widschwendter Peter, De Gregorio Nikolaus, Bekes Inga, Janni Wolfgang, Davut Dayan, Huober Jens
Alpha-smooth muscle actin expression in the stroma predicts resistance to trastuzumab in patients with early-stage HER2-positive breast cancer
Vathiotis I, Kim S, Harbeck N, Gomez H, Shafi S, Syrigos K, Fountzilas G, Sotiriou C, Pusztai L, Warren S, Di Cosimo S, Huober J, Nuciforo P, Moutafi M, Divakar P, Aung T, Qing T, Fernandez A, Yaghoobi V, El-Abed S, Wang Y, Guillaume S, Rimm D. Alpha-smooth muscle actin expression in the stroma predicts resistance to trastuzumab in patients with early-stage HER2-positive breast cancer. Clin Cancer Res 2021
31.08.2021Alpha-smooth muscle actin expression in the stroma predicts resistance to trastuzumab in patients with early-stage HER2-positive breast cancer
31.08.2021Clin Cancer Res 2021
Vathiotis Ioannis A, Kim Sung-Bae, Harbeck Nadia, Gomez Henry, Shafi Saba, Syrigos Konstantinos N, Fountzilas George, Sotiriou Christos, Pusztai Lajos, Warren Sarah, Di Cosimo Serena, Huober Jens, Nuciforo Paolo, Moutafi Myrto K, Divakar Prajan, Aung Thazin Nwe, Qing Tao, Fernandez Aileen, Yaghoobi Vesal, El-Abed Sarra, Wang Yingbo, Guillaume Sébastien, Rimm David L
A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, With or Without Ribociclib or Alpelisib, in Patients with Estrogen Receptor-Positive Breast Cancer
Jhaveri K, De Vita S, Crystal A, He W, Ji Y, Balbin A, Sheng Q, Kundamal N, Huober J, Takahashi S, Terret C, Duhoux F, Layman R, Cresta S, Yap Y, Juric D, Curigliano G. A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, With or Without Ribociclib or Alpelisib, in Patients with Estrogen Receptor-Positive Breast Cancer. Clin Cancer Res 2021
25.08.2021A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, With or Without Ribociclib or Alpelisib, in Patients with Estrogen Receptor-Positive Breast Cancer
25.08.2021Clin Cancer Res 2021
Jhaveri Komal, De Vita Serena, Crystal Adam, He Wei, Ji Yan, Balbin Alejandro, Sheng Qing, Kundamal Nicole, Huober Jens, Takahashi Shunji, Terret Catherine, Duhoux Francois P, Layman Rachel M, Cresta Sara, Yap Yoon-Sim, Juric Dejan, Curigliano Giuseppe
Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2)
Möbus V, Reinisch M, Link T, Sinn B, Janni W, Denkert C, Furlanetto J, Engels K, Solbach C, Schmatloch S, Rey J, Burchardi N, Loibl S, Stickeler E, Huober J, Lück H, Ladda E, Klare P, Schmidt M, Schneeweiss A, Grischke E, Wachsmann G, Forstbauer H, Untch M, Marme F, Blohmer J, Jackisch C, GBG and AGO-B. Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2). Eur J Cancer 2021; 156:138-148.
24.08.2021Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2)
24.08.2021Eur J Cancer 2021; 156:138-148
Möbus Volker, Reinisch Mattea, Link Theresa, Sinn Bruno V, Janni Wolfgang, Denkert Carsten, Furlanetto Jenny, Engels Knut, Solbach Christine, Schmatloch Sabine, Rey Julia, Burchardi Nicole, Loibl Sibylle, Stickeler Elmar, Huober Jens, Lück Hans-Joachim, Ladda Ekkehart, Klare Peter, Schmidt Marcus, Schneeweiss Andreas, Grischke Eva-Maria, Wachsmann Grischa, Forstbauer Helmut, Untch Michael, Marme Frederik, Blohmer Jens-Uwe, Jackisch Christian, GBG and AGO-B
Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical Trial
Friedl T, Tesch H, Mahner S, Brucker S, Heinrich G, Häberle L, Fasching P, Beckmann M, Coleman R, Janni W, Schneeweiss A, Jückstock J, Fehm T, Müller V, Lichtenegger W, Blohmer J, Lorenz R, Forstbauer H, Fink V, Bekes I, Huober J, Rack B. Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical Trial. JAMA Oncol 2021; 7:1149-1157.
01.08.2021Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical Trial
01.08.2021JAMA Oncol 2021; 7:1149-1157
Friedl Thomas W P, Tesch Hans, Mahner Sven, Brucker Sara Y, Heinrich Georg, Häberle Lothar, Fasching Peter A, Beckmann Matthias W, Coleman Robert E, Janni Wolfgang, Schneeweiss Andreas, Jückstock Julia, Fehm Tanja, Müller Volkmar, Lichtenegger Werner, Blohmer Jens, Lorenz Ralf, Forstbauer Helmut, Fink Visnja, Bekes Inga, Huober Jens, Rack Brigitte
Copy number aberration analysis to predict response to neoadjuvant anti-HER2 therapy: results from the NeoALTTO phase III clinical trial
Venet D, Gomez H, Semiglazov V, de Azambuja E, Huober J, Nuciforo P, Di Cosimo S, Piccart-Gebhart M, Loi S, Rothé F, Saura C, Wang Y, Rediti M, Maetens M, Fumagalli D, Brown D, Majjaj S, Salgado R, Pusztai L, Harbeck N, El-Abed S, Sotiriou C. Copy number aberration analysis to predict response to neoadjuvant anti-HER2 therapy: results from the NeoALTTO phase III clinical trial. Clin Cancer Res 2021
28.07.2021Copy number aberration analysis to predict response to neoadjuvant anti-HER2 therapy: results from the NeoALTTO phase III clinical trial
28.07.2021Clin Cancer Res 2021
Venet David, Gomez Henry, Semiglazov Vladimir, de Azambuja Evandro, Huober Jens, Nuciforo Paolo, Di Cosimo Serena, Piccart-Gebhart Martine, Loi Sherene, Rothé Françoise, Saura Cristina, Wang Yingbo, Rediti Mattia, Maetens Marion, Fumagalli Debora, Brown David N, Majjaj Samira, Salgado Roberto, Pusztai Lajos, Harbeck Nadia, El-Abed Sarra, Sotiriou Christos